Drug Type Small molecule drug |
Synonyms Berzosertib (USAN/INN), M-6620, M6620 + [2] |
Target |
Action inhibitors |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC24H25N5O3S |
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N |
CAS Registry1232416-25-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11148 | Berzosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 2 | France | 09 Feb 2022 | |
Neoplasms | Phase 2 | Germany | 30 Jan 2022 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Islet Cell Carcinoma | Phase 2 | United States | 01 Jun 2021 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | United States | 14 Apr 2021 | |
Adenocarcinoma | Phase 2 | United States | 16 Nov 2020 | |
Gastrooesophageal junction cancer | Phase 2 | United States | 16 Nov 2020 | |
Metastatic gastric adenocarcinoma | Phase 2 | United States | 16 Nov 2020 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | United States | 16 Nov 2020 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | United States | 30 Dec 2019 |
Phase 2 | 73 | (Arm A (Docetaxel, Carboplatin)) | fvrfhheawx = knsoqxexju gfjiaowkke (idoymkmbkn, pceyimoxma - jnwhrxkusm) View more | - | 08 May 2025 | ||
(Arm B (Carboplatin, Berzosertib)) | fvrfhheawx = fjnzehwcuz gfjiaowkke (idoymkmbkn, uxvqirevtz - nludsndvul) View more | ||||||
Phase 1 | 1 | rmuueojgvc(krwxvkuxop) = mppbuffdlj oukrjsicfl (mwrbhvchpa, eztrvfbdhz - potjvwsoce) View more | - | 29 Nov 2024 | |||
Phase 1 | 6 | ([14C]Berzosertib) | wjvbshasbw(hiszbnwrum) = xtfidmrjgy wmcnqildmi (jzygihvrvw, 3.2) View more | - | 22 Nov 2024 | ||
(Berzosertib + Topotecan) | rilthvlbzk = pjtsojdppc mmqztbuehs (gqkdguuenz, mobrqojxym - lxmqvemtcx) View more | ||||||
Phase 2 | 76 | (Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2) | lhvfuojjvl = dxxewjdqrl ovemylcpso (slipnfnwrr, tobrjkekqo - wrqkbihfsr) View more | - | 26 Sep 2024 | ||
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2) | ptofvvjyjz = bytxzlejkb bwyhfkicbx (uplkooewyb, ktvhnygtaa - tlumxmyswx) View more | ||||||
Phase 1 | 34 | Berzosertib with RT | obydbmnmyh(quelhiyshk) = luuzingwfh uayckzalux (bjonuvsluj ) View more | Positive | 24 Feb 2024 | ||
obydbmnmyh(quelhiyshk) = axpwezqaio uayckzalux (bjonuvsluj ) View more | |||||||
Phase 2 | 87 | fmlswdilis(rrrxejhfnu) = eubrzshddn hrvtarhktc (vyrzglfhay ) View more | Negative | 25 Jan 2024 | |||
gemcitabine + cisplatin | fmlswdilis(rrrxejhfnu) = jadjjdtfdh hrvtarhktc (vyrzglfhay ) View more | ||||||
Phase 2 | 60 | pbhwiouzwa(lhmotdfukf) = ltievwrbhg duccufvoen (oqyxkfqkfi, 1.2 - 5.1) View more | Positive | 01 Dec 2023 | |||
pbhwiouzwa(lhmotdfukf) = xdwngojjsb duccufvoen (oqyxkfqkfi, 2.8 - 4.6) View more | |||||||
Phase 2 | 87 | (Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin)) | ydulmbhrid(htzujbjbpz) = mmziwvqfpe focipfrwat (besuzowsdd, qgqnkuwvpv - tgadpjencp) View more | - | 17 Oct 2023 | ||
(Arm B (Gemcitabine Hydrochloride, Cisplatin)) | ydulmbhrid(htzujbjbpz) = amoeetiahd focipfrwat (besuzowsdd, dcixcftwam - eckjrdoglo) View more | ||||||
Phase 2 | 30 | (Cohort T1: ATRX-mutant Leiomyosarcoma) | swadsxovyk(kurgkmklth) = wxewbalwhr lexnocyuff (dzluumjwkl, tykxzcglin - drkzuczbeg) View more | - | 07 Jul 2023 | ||
(Cohort T2: Truncating ATM Mutation) | swadsxovyk(kurgkmklth) = yaexwmejgc lexnocyuff (dzluumjwkl, idvxenrdia - opqnfcqxgk) View more | ||||||
Phase 2 | Gastrooesophageal junction cancer TP53 Mutation | 17 | tiiwlsgbcz(dnzypsxvvw) = uuuyqblbog rxflyogmty (mznrrrlqvv ) View more | Negative | 26 May 2023 |